SPDW - ETF AI Analysis
Top Page
SPDR Portfolio Developed World ex-US ETF (SPDW)
SPDW’s rating suggests it is a solid but not top-tier international fund, helped by strong holdings like Novartis, AstraZeneca, and HSBC, which show healthy financial performance, positive earnings sentiment, and generally supportive technical trends. These strengths are partly offset by risks such as high valuations or overbought signals in several key stocks, plus company-specific issues like leverage and negative free cash flow at Mitsubishi UFJ and growth challenges at Shell. The main risk factor is that a meaningful portion of the fund is tied to large financial and healthcare names, so sector-specific setbacks or valuation corrections in these areas could weigh on overall performance.
SPDW vs. SPDR S&P 500 ETF (SPY)
- AUM
- 41.36B
- Region
- Developed Markets
- Expense Ratio
- 0.03%
- Beta
- 0.76
- Issuer
- State Street
- Inception Date
- Apr 20, 2007
- Dividend Yield
- 3.07%
- Asset Class
- Equity
- Index Tracked
- S&P Developed x United States BMI
SPDW Summary
SPDR Portfolio Developed World ex-US ETF (SPDW) is a fund that follows the S&P Developed ex-U.S. Index, giving you stock market exposure to developed countries like Japan, the UK, and Canada while leaving out the United States. It owns a wide mix of companies of all sizes and sectors, including well-known names like Samsung Electronics, Nestlé, and ASML. Investors might consider SPDW to diversify beyond the U.S. and tap into long-term growth in other major economies. A key risk is that international stock prices can go up and down with global markets and currency swings.
How much will it cost me?
This ETF has an expense ratio of 0.03%, which means you’ll pay about $0.30 per year for every $1,000 invested. That’s much lower than the average ETF because SPDW is a passively managed fund that simply tracks an index instead of paying managers to pick individual stocks.
What would affect this ETF?
SPDW could benefit if developed markets outside the U.S. see steady economic growth, supportive interest rate policies, and strong demand for technology, financials, and healthcare, which would help major holdings like Samsung, ASML, and large global banks and drugmakers. On the downside, slower growth in Europe or Asia, banking or energy sector stress, currency swings versus the U.S. dollar, or new regulations affecting big international companies could weigh on the ETF’s performance.
SPDW Top 10 Holdings
SPDW’s story is all about big overseas players, with a clear tilt toward non-U.S. tech and global blue chips. Samsung and SK hynix have been losing steam lately, so their weakness has been a bit of a drag despite strong gains earlier in the year. ASML, another chip heavyweight, has seen mixed momentum but still helps anchor the fund’s tech exposure. On the brighter side, steady climbers like Roche, Novartis, and Shell are quietly pulling their weight, showing how Europe and developed Asia together drive this globally diversified lineup.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 GB:SMSN | Samsung Electronics | 2.29% | $933.69M | $1.07T | 124.13% | ―― |
 KR:000660 | SK hynix Inc. | 1.89% | $770.07M | KRW 1033.53T | 163.33% | ―― |
 NL:ASML | ASML Holding NV | 1.86% | $758.87M | EUR 539.67B | 53.36% | 76Outperform |
 RHHVF | Roche Holding AG | ― | ― | ― | ― | 73Outperform |
 GB:SHEL | Shell (UK) | 0.96% | $390.66M | GBP 229.30B | 37.70% | 73Outperform |
 GB:HSBA | HSBC Holdings | 0.89% | $363.83M | GBP 218.81B | 20.69% | 80Outperform |
 CH:NOVN | Novartis AG | 0.91% | $370.71M | CHF 244.89B | 32.49% | 80Outperform |
 RY | Royal Bank Of Canada | ― | ― | ― | ― | 75Outperform |
 AZN | AstraZeneca | ― | ― | ― | ― | 80Outperform |
 JP:8306 | Mitsubishi UFJ Financial Group | 0.81% | $330.59M | JPY 38.80T | 45.19% | 76Outperform |
SPDW Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For SPDW, the sentiment is Negative. The current price of 49.45 is below the 20-day moving average (MA) of 49.62, below the 50-day MA of 50.59, and above the 200-day MA of 49.03, indicating a neutral trend. The MACD of -0.27 indicates Negative momentum. The RSI at 44.70 is Neutral, neither overbought nor oversold. The STOCH value of 62.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SPDW.
SPDW Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| SPDW | $49.45 | $52.00(5.16% Upside) | $41.36B | 0.03% | 61Neutral |
 VEA | $69.61 | $88.07(26.52% Upside) | $228.75B | 0.03% | 58Neutral |
 SCHF | $27.02 | $33.78(25.00% Upside) | $67.71B | 0.03% | 61Neutral |
 IDEV | $89.51 | $107.49(20.08% Upside) | $33.80B | 0.04% | 66Neutral |
 AVDE | $89.39 | $108.79(21.70% Upside) | $19.44B | 0.23% | 65Neutral |
 DFAI | $41.53 | $49.77(19.85% Upside) | $18.27B | 0.18% | 64Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SPDW | SPDR Portfolio Developed World ex-US ETF | 49.45 | 7.74 | 18.57% | |
| VEA | Vanguard FTSE Developed Markets ETF | 69.61 | 10.85 | 18.46% | |
| SCHF | Schwab International Equity ETF | 27.02 | 4.28 | 18.84% | |
| IDEV | iShares Core MSCI International Developed Markets ETF | 89.51 | 12.30 | 15.93% | |
| AVDE | Avantis International Equity ETF | 89.39 | 13.16 | 17.26% | |
| DFAI | Dimensional International Core Equity Market ETF | 41.53 | 6.17 | 17.46% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.